Grace Gifford

Grace Gifford

Auto-generated profile, based on publicly available information

Grace Gifford

Department of Haematology and Transfusion Royal North Shore Hospital St Leonards Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 May 2016 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
GGG Gifford
G Gifford
NGN Gilroy
N Gilroy
GDG Dyer
G Dyer
LBL Brice
L Brice
MKM Kabir
M Kabir
IKI Kerridge
I Kerridge

4 April 2020 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
GGGrace K. Gifford
Grace K. Gifford
AGAndrew J. Gifford
Andrew J. Gifford
QCQian Chen
Qian Chen
YSYandong Shen
Yandong Shen
SGSara Gabrielli
Sara Gabrielli
OBOliver Giles Best
Oliver Giles Best
Fatty acid synthesis is crucial in supporting the survival and proliferation of multiple forms of cancer. The high metabolic demands of fatty acid synthesis are regulated by the AMP-activated kinase and activity of the fatty acid synthase enzyme. In this study, the roles of these enzymes in diffuse large B-cell lymphoma (DLBCL) were investigated by genetic knock-down and pharmacological activation of AMP-activated kinase by metformin, and selective inhibition of fatty acid synthase using the novel drug Fasnall. We observed distinct heterogeneity and adaptive plasticity of lipid metabolism in a panel of DLBCL cell lines and demonstrate the therapeutic potential of inhibiting fatty acid synthesis in a subset of DLBCL cells. The translational relevance of these in vitro data is supported by the strong correlation between AMP-activated protein kinase expression in primary DLBCL samples and disease relapse. Inhibition of fatty acid synthase with Fasnall may represent a therapeutic option for DLBCL that preferentially subverts to de novo fatty acid synthesis.

22 January 2021 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GGGrace Gifford
Grace Gifford
LHLuke Hesson
Luke Hesson
JWJason W. H. Wong
Jason W. H. Wong
ACAdam Carroll
Adam Carroll
SGSara Gabrielli
Sara Gabrielli
MGMatthew Greenwood
Matthew Greenwood

15 February 2017 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
GGGrace Gifford
Grace Gifford
SGSara Gabrielli
Sara Gabrielli
AGAnthony Gill
Anthony Gill
MGMatthew Greenwood
Matthew Greenwood
KWKelly Wong
Kelly Wong
WSWilliam Stevenson
William Stevenson

29 July 2020 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
GGGrace Gifford
Grace Gifford
WSWilliam Stevenson
William Stevenson
GBGiles Best
Giles Best
Current chemoimmunotherapy is unable to cure up to 40% of patients diagnosed with diffuse large B-cell lymphoma (DLBCL). Targeting the mechanisms by which DLBCL evades apoptosis is crucial to overcoming treatment failure in this heterogeneous disease as both current and novel treatments depend on the apoptosis of malignant cells. Despite the common overexpression of BCL-2, venetoclax is ineffective in DLBCL due to MCL-1 co-expression. This is driven by pro-growth PI3-kinase signaling, which is promoted in turn by PIM kinases. In this study, the novel dual-kinase inhibitor, IBL-202, was combined with venetoclax against a panel of DLBCL cell lines that have variable expression of pro-survival proteins. The results support the efficacy of simultaneously targeting inter-related molecules to overcome apoptotic escape in this biologically heterogeneous disease. As venetoclax, pan-PIM-kinase and pan-PI3-kinase inhibitors have, or are currently being studied in clinical trials, it may be rational to consider these drugs in combination for the treatment of DLBCL.